Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  SARS-CoV 2 Viral Infection COVID 19 SARS-CoV-2 infection confirmed by polymerase chain reaction assay (PCR) from a nasopharyngeal swab or other accepted specimen type. (If testing was performed ≥ 5 days before enrollment, this must be repeated and accept only if positive again). Date of COVID test must be ≤ 5 days prior to infusion. 2. Currently hospitalized adult patient (≥ 18 years of age) requiring medical care for COVID19 3. Peripheral oxygen saturation (SpO2) ≥ 92% on room air 4. Hgb ≥ 7.0 gm/dl 5. Negative pregnancy test (if applicable) 6. Patient or parent/guardian capable of providing informed consent (may be obtained electronically) 7. Evidence of pulmonary infiltrates on chest imaging. Any chest imaging findings which would be consistent with COVID19 would qualify (Eg: ground glass opacities, multifocal infiltrates etc.) 8. High risk of requiring mechanical ventilation as defined by at least two of the following: 1. Age ≥ 60 years of age 2. Age ≥ 75 years of age (counts as meeting two criteria) 3. Hypertension (HTN) 4. Chronic cardiovascular disease other than HTN (eg: Coronary artery disease, congestive heart failure or cardiomyopathies). 5. Diabetes Mellitus 6. Obesity (BMI ≥ 30) 7. Obesity (BMI ≥ 40, counts as meeting two criteria) 8. Active cancer diagnosis or ongoing (within 3 months) cytotoxic chemo/ radio-therapy for a cancer 9. Post-hematopoeitic stem cell or solid organ transplantation status 10. Immunodeficiency states including HIV infection on antiretroviral therapy (except those listed as  #1, #7 and #10) as determined by the treating physician (eg: receiving immunosuppressive therapy like rituximab or congenital immunodeficiency syndromes, prior treatment with chemotherapy greater than 3 months ago but per investigators discretion could have lingering effects on the immune system, eg: chemotherapy regimens for lymphomas, ALL or AML etc.) 11. Chronic obstructive pulmonary disease (COPD) 12. Current everyday smoker 13. Chronic kidney disease (eGFR < 30 mL/min/1.73 m2 ) 14. Bronchial asthma (on active treatment prior to admission, eg. Use of rescue inhalers or inhaled corticosteroids or other treatments to prevent/treat attacks) Received Anti-thymocyte globulin (ATG), Campath or other T cell immunosuppressive monoclonal antibodies in the 28 days prior to screening for enrollment 2. Requiring mechanical ventilation at time of T cell infusion 3. Alanine aminotransferase or aspartate aminotransferase greater than 5 x upper limit of normal 4. If previously undergone an allogeneic hematopoietic stem cell transplant and have evidence of active acute GVHD greater than or equal to grade 2 5. Uncontrolled relapse of malignancy 6. Requiring vasopressors 7. Known history of autoimmune disease except prior thyroiditis 8. Is not suitable at the discretion of the treating physician 9. Patients on greater than 6mg/day of dexamethasone (IV) or equivalent 10. Greater than grade 1 CRS per American Society for Transplantation and Cellular Therapy (ASTCT) 11. Patients should not be enrolled on any other interventional clinical trials for COVID19. Patients may receive routine care for COVID19 per institutional standards (including antivirals such as remdesivir or other FDA-EUA approved products and thromboprophylaxis)